Human anti-pneumococci antibody produced by an Epstein Barr virus (EBV)-immortalized cell line

M. Steinitz, S. Tamir, A. Goldfarb

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Anti-pneumococcal antibody-producing lymphocytes from a patient who was immunized with Pneumovax (a polysaccharide mixture from 14 different pneumococci types) were selected and immortalized with Epstein Barr virus (EBV). The cells of the emerging cloned line were shown on a single cell level assay to secrete an IgM, κ anti-pneumococci antibody. This human monoclonal antibody bound specifically to polysaccharides of pneumococci type 8, but did not bind to any of the other 13 pneumococci types that were present in the Pneumovax mixture. In competition experiments, inhibition of binding occurred with polysaccharide type 8 and Pneumovax only. This diploid cell line has actively secreted the specific antibody (2.8 μg/106 cells/ml) now for more than 9 mo. In patients, increased anti-pneumococcal antibody titers generated by active immunization with Pneumovax improves resistance to the corresponding bacterial infection. Production in vitro of human monoclonal antibodies directed toward bacterial and viral antigens enables a new possible approach for passive immune protection.

Original languageEnglish
Pages (from-to)877-882
Number of pages6
JournalJournal of Immunology
Volume132
Issue number2
StatePublished - 1984
Externally publishedYes

Fingerprint

Dive into the research topics of 'Human anti-pneumococci antibody produced by an Epstein Barr virus (EBV)-immortalized cell line'. Together they form a unique fingerprint.

Cite this